CN100342879C - Liver fibrosis treating prepn and its process - Google Patents
Liver fibrosis treating prepn and its process Download PDFInfo
- Publication number
- CN100342879C CN100342879C CNB2005100186641A CN200510018664A CN100342879C CN 100342879 C CN100342879 C CN 100342879C CN B2005100186641 A CNB2005100186641 A CN B2005100186641A CN 200510018664 A CN200510018664 A CN 200510018664A CN 100342879 C CN100342879 C CN 100342879C
- Authority
- CN
- China
- Prior art keywords
- preparation
- hepatic fibrosis
- treatment
- medicine
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000019425 cirrhosis of liver Diseases 0.000 title abstract description 16
- 238000000034 method Methods 0.000 title abstract description 8
- 230000008569 process Effects 0.000 title abstract description 3
- 239000003814 drug Substances 0.000 claims abstract description 44
- 206010019668 Hepatic fibrosis Diseases 0.000 claims abstract description 41
- 238000002360 preparation method Methods 0.000 claims abstract description 31
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 7
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 60
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 10
- 239000009636 Huang Qi Substances 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 229940126678 chinese medicines Drugs 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 2
- 238000012869 ethanol precipitation Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000002481 ethanol extraction Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- 210000004185 liver Anatomy 0.000 abstract description 19
- 208000006454 hepatitis Diseases 0.000 abstract description 18
- 206010008909 Chronic Hepatitis Diseases 0.000 abstract description 13
- 230000017531 blood circulation Effects 0.000 abstract description 12
- 208000024891 symptom Diseases 0.000 abstract description 10
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 102000006395 Globulins Human genes 0.000 abstract description 8
- 108010044091 Globulins Proteins 0.000 abstract description 8
- 210000002784 stomach Anatomy 0.000 abstract description 8
- 210000003734 kidney Anatomy 0.000 abstract description 7
- 102000007562 Serum Albumin Human genes 0.000 abstract description 5
- 108010071390 Serum Albumin Proteins 0.000 abstract description 5
- 206010041660 Splenomegaly Diseases 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 231100000283 hepatitis Toxicity 0.000 abstract description 5
- 230000001502 supplementing effect Effects 0.000 abstract description 5
- 208000002672 hepatitis B Diseases 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000007812 deficiency Effects 0.000 abstract description 2
- 230000008506 pathogenesis Effects 0.000 abstract description 2
- 241000212941 Glehnia Species 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 102000010909 Monoamine Oxidase Human genes 0.000 description 9
- 108010062431 Monoamine oxidase Proteins 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000002651 drug therapy Methods 0.000 description 7
- 229920002674 hyaluronan Polymers 0.000 description 7
- 229960003160 hyaluronic acid Drugs 0.000 description 7
- 210000003240 portal vein Anatomy 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000004761 fibrosis Effects 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 102000002734 Collagen Type VI Human genes 0.000 description 2
- 108010043741 Collagen Type VI Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 208000005946 Xerostomia Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000019633 pungent taste Nutrition 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000000955 splenic vein Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VSDWHZGJGWMIRN-UHFFFAOYSA-N 3-methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one Chemical compound CC(C)CC(=O)C1=C(O)C=C(O)C=C1O VSDWHZGJGWMIRN-UHFFFAOYSA-N 0.000 description 1
- 208000004130 Blepharoptosis Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004594 appetite change Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 201000008865 drug-induced hepatitis Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001936 exophthalmos Diseases 0.000 description 1
- -1 filters Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000004154 testing of material Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a preparation for treating hepatic fibrosis, and a preparation method thereof. The preparation for treating hepatic fibrosis comprises the following raw medicinal materials: 15 to 150 parts by weight of astragalus root, 15 to 150 parts by weight of coastal glehnia root, 15 to 150 parts by weight of rehmannia root and 3 to 30 parts by weight of panax notoginseng. The medicine prescription is developed by combining Chinese medicine theories with modern medicine and pharmacy methods. The medicine of the present invention promotes blood circulation for removing blood stasis without warm dampness, and supplements qi and nourishes yin without obstructing stomach fluid production. Multiple medicines are combined for use. The preparation has the functions of promoting blood circulation for removing blood stasis, supplementing qi, nourishing yin and tonifying the liver and the kidney, and treats both manifestations and the root causes of diseases according to the pathogenesis of the stagnation of QI and blood and the deficiency of liver yin and kidney yin in the process of hepatic fibrosis. The medicine of the present invention can improve hepatitis clinical symptoms, can improve serum albumin, can reduce globulin, can retract splenomegaly, and can reduce blood serum hepatic fibrosis indexes. The prepatation also has the advantages of convenient administration, safety and low price. Because China is a country with a great population with hepatitis B and the incidence rates of chronic hepatitis and hepatic cirrhosis are high, the medicine has wide application prospect.
Description
Technical field:
The present invention relates to a kind of medicine, relate in particular to a kind of medicine for the treatment of hepatic fibrosis.
Background technology:
Hepatic fibrosis be development of chronic hepatitis be liver cirrhosis total pathological change and must be through approach, hepatic fibrosis is reversible, liver cirrhosis then is irreversible.Stop the formation of hepatic fibrosis, significant to preventing to develop into liver cirrhosis.The Chinese medicine anti-hepatic fibrosis has certain advantage, but treats adopt many based on drug for invigorating blood circulation and eliminating stasis at present, is aided with replenishing QI to invigorate the spleen, softening the hard mass merit knot, nourishing the liver and kidney, does not see the reported in literature of blood circulation promoting and blood stasis dispelling and supplementing QI and nourishing YIN medicine compatibility treatment hepatic fibrosis.
Summary of the invention:
The object of the present invention is to provide the preparation and preparation method thereof of the treatment hepatic fibrosis of a kind of activating blood circulation to dissipate blood stasis, liver and kidney tonifying, treating both the principal and secondary aspects of a disease
Technical scheme of the present invention is as follows:
1, the preparation of treatment hepatic fibrosis: it comprises the crude drug of following ratio of weight and number, Radix Astragali 15-150 part, Radix Glehniae 15-150 part, Radix Rehmanniae 15-150 part, Radix Notoginseng 3-30 part.
2, the preparation method of treatment hepatic fibrosis preparation:
(1) Radix Salviae Miltiorrhizae, Radix Notoginseng, the Radix Astragali three flavor Chinese medicines are directly pulverized, it is standby to get fine powder;
(2) with the remaining coarse powder of step (1) with other crude drug, adopt that the preparation method of existing Chinese patent medicine is carried out infusion, filtration, concentrated, ethanol precipitation, filtration, recovery ethanol, concentrate and put cold;
(3) with the fine powder of step (1) and step (2) concentrate and with put cold thing mix homogeneously, make medicament.
This medicine prescription is developed in conjunction with modern medicine, method of pharmacy according to theory of Chinese medical science.The present invention mainly is the anti-hepatic fibrosis pathological changes, clinically is used for the treatment of chronic hepatitis, early stage liver cirrhosis.But this medicine is blood circulation promoting and blood stasis dispelling both, again supplementing QI and nourishing YIN.So this medicine blood circulation promoting and blood stasis dispelling is not too crossed warm-dryness syndrome again; Supplementing QI and nourishing YIN and do not hinder stomach and give birth to wet.All medicines share, at the pathogenesis of the stagnation of QI and blood hepatic and renal YIN deficiency in the liver fibrosis process, and blood circulation promoting and blood stasis dispelling, supplementing QI and nourishing YIN, liver and kidney tonifying, treating both the principal and secondary aspects of a disease.No matter zoopery of medicine of the present invention, or clinical experiment all demonstrates good result.Can improve the hepatitis clinical symptoms, improve serum albumin, reduce globulin, the splenomegaly retraction reduces the serum hepatic fibrosis index, and taking convenience, safety, and cheap.Because China is hepatitis B big country, the incidence rate height of chronic hepatitis, liver cirrhosis.Therefore this medical instrument has broad application prospects.
The specific embodiment:
1, the preparation of treatment hepatic fibrosis: it comprises the crude drug of following ratio of weight and number, Radix Astragali 15-150 part, Radix Glehniae 15-150 part, Radix Rehmanniae 15-150 part, Radix Notoginseng 3-30 part, Semen Persicae 10-100 part, Rhizoma Chuanxiong 9-90 part, Fructus Crataegi 15-150 part, Poria 10-100 part, Radix Angelicae Sinensis 9-90 part, Radix Salviae Miltiorrhizae 15=150 part, Radix Paeoniae Rubra 15-150 part.
2, the preparation method of treatment hepatic fibrosis preparation:
(1) Radix Salviae Miltiorrhizae, Radix Notoginseng, the Radix Astragali three flavor Chinese medicines is directly pulverized, got 80 mesh sieves or 80 orders are standby with the top sieve fine powder;
(2) the remaining coarse powder of step (1) adds the water infusion 2 times with other crude drug, boils 1 hour at every turn, merges to boil liquid, filters, filtrate concentrates, and puts coldly, adds 95% ethanol and reaches 70% to containing the alcohol amount, leaves standstill 24 hours, filters, and gets filtrate for later use;
(3), and be concentrated into the thick paste shape with above-mentioned decompression filtrate recycling ethanol, put cold, add above-mentioned fine powder, make granule, drying, compacting is in flakes or incapsulate.
One, the acute toxicity test of medicament of the present invention:
1 material
1.1 30 of laboratory animal KM kind mices, cleaning level, body weight 19.84 ± 1.42g, male and female half and half, raising in 19~30 ℃, humidity is 55%~60%, throws mice standard particle material.Provide by Colleges Of Traditional Chinese Medicine Of Fujian's Experimental Animal Center.The animal quality certification number: No. the 003rd, Chinese Academy of Medical Sciences's the care of animal.
1.2 being subjected to the reagent thing is medicament of the present invention, is provided by Fuzhou City Infectious Disease Hospital, gets this medicine 7g and is made into 10ml solution with distilled water, every mice gavages the 0.4ml/10g body weight 1 time.
2 test methods
2.1 10 of mices are got in trial test, water is can't help in the 12h fasting before the experiment.Make Cmax (just by irritating the stomach syringe needle with medicament of the present invention, do not cause the concentration 700mg/ml that former pharmacology, voltinism shape change), maximal dose (0.4ml/10g body weight, every≤1ml) irritate stomach 1 time, observe dead mouse number and general situation in 7 days, if do not have death, then ask 1 maximum tolerated dose (MTD); If death toll 〉=30%, then use " karber's method " ask median lethal dose(LD 50) (LD50).
2.2 1 week of test mice adaptability sub-cage rearing is made 1 mtd test for 400 times with human oral dosage behind the 12h on an empty stomach, free diet after the administration, and every day at the upper and lower noon respectively observes 1 time, observes continuously 7 days.
3 observation index
3.1 1. behavior and reaction of nervous system (comprise undesired cry, agitation, uneasiness, irritability, hyperesthesia, few moving, drowsiness or stupor etc.); 2. motion (comprising muscle twitches, stiff, forced movement, lax, paralysis etc.); 3. pupil and secretions (pupil have do not dwindle or amplify, sialorrhea is shed tears etc.).
3.2 breathe and the cardiovascular-respiratory state, pareordia heart rate speed etc. is touched in the nose secretion.
3.3 gastrointestinal abdominal part flatulence or contraction, stool character and color and luster.
3.4 genitourinary system labia, mammary gland swelling, perineal position dirt.
3.5 skin and hair color, integrity has or not hyperemia, and cyanosis is pale, dermexanthesis, and fur is loose etc.
3.6 eye has or not blepharoptosis, exophthalmos trembles etc.
3.7 other appetite and body weight change, measure every day.
4 results
4.1 trial test animal does not as a result have death, so ask MTD.
4.2 state all observation index during experimental observation are no abnormal before and after the filling stomach.
4.3 body weight and feed consumption see Table 1 before and after the filling stomach.
Table 1 is irritated the (x ± s) of mice body weight and every day food consumption thing before and after the stomach
D number after the administration | The example number | Body weight | Only consume feedstuff g/ |
0 1 2 3 4 5 6 | 20 20 20 20 20 20 20 | 19.84±1.42 20.51±1.42 21.18±1.68 22.13±1.97 23.08±2.05 23.88±2.17 24.63±2.30 | 4.78±0.34 5.05±0.12 5.15±0.12 5.27±0.25 5.35±0.30 5.40±0.38 5.40±0.42 |
Table 1 shows the mice body weight still by the physiological conditions normal growth, and every day, feed consumption did not have significant change.
5 conclusions
Medicament of the present invention has replenishing QI to invigorate the spleen, the blood circulation promoting and blood stasis dispelling effect of nourishing the liver and kidney of holding concurrently.Carry out mtd test with the KM mice.The present invention is with 1 tolerance test the most much of 400 times of works of population dosing, and observed every index is all normal, does not see 1 animal dead.Result of the test proof medicament of the present invention does not have obvious acute toxicity effect.
Two, the clinical trial visual report of medicament anti-hepatic fibrosis of the present invention is as follows
1 materials and methods
1.1 testing of materials object is chronic hepatitis patient 200 examples of coming institute's diagnosis and treatment, wherein male 170 examples, women 30 examples; 11~55 years old age is by nineteen ninety-five whole nation infectious disease parasite requirement meeting revision diagnostic criteria.
1.2 adding, method (1) uses medicament of the present invention on the basis of the liver protecting and ALT lowering treatment; Each 4, every day 3 times, 3 months be 1 course of treatment, continuous 2 courses of treatment of having.(2) observe the symptoms respectively before and after the treatment sign, liver function wadding turbidity, serum albumin, globulin, hepatic fibrosis III procollagen type peptide (PIVP), IV Collagen Type VI (IV-C), monoamine oxidase, MAO (MAO), hyaluronic acid four indices such as (HA).(3) partly case hepatic tissue specimen is worn acquisition for the percutaneous liver.
1.3 statistical procedures adopts significant t-test
2 results
2.1 after 1~2 course of treatment, its clinical manifestation and laboratory result all show satisfied curative effect, see Table 1~3 through pharmaceutical treatment of the present invention:
The variation of table 1 200 routine hepatitis clinical manifestations after Drug therapy of the present invention
Clinical manifestation | Treatment precedent number | Routine number is recovered in the treatment back | Effective percentage % | |
Treated back 3 months | Treated back 6 months | |||
Weak pain in the hepatic region or uncomfortable dim complexion body of the tongue blood stasis | 138 120 133 106 | 125 96 90 81 | 128 03 111 95 | 92.75 85.83 83.46 89.62 |
Table 2 200 routine hepatitis are biochemistry and the inspection of B ultrasonic spleen after Drug therapy of the present invention
Project | Treatment precedent number | Routine number is improved in the treatment back | Effective percentage % | |
Routine number takes a turn for the better | Positive common practice number | |||
Wadding turbidity raising albumin (<35g/L) globulin (>35g/L) splenomegaly | 142 73 108 155Δ | 70 31 36 85 | 49 24 55 35 | 83.8 75.64 84.26 86.96 |
Δ is checked 145 examples, wherein 7 routine no changes
Table 3 200 routine hepatitis are through the variation of 4 indexs of Drug therapy heptic fibrosis of the present invention (x ± S)
Project | Before the treatment | After the treatment | P |
HA(ng/ml) MAO(u/L) PIIIP(ug/L) | 366.20±277.41 44.15±12.37 1.297±1.039 | 144.00±138.20 40.39±2.41 0.972±1.534 | <0.001 <0.001 <0.05 |
IV-C(ng/L) | 204.82±186.4 | 95.67±52.36 | <0.001 |
2.2 it is 1.23 ± 0.12cm that Dsv, inner diameter of portal vein change the preceding inner diameter of portal vein of treatment, is 1.18 ± 0.09cm after the treatment, P<0.001 is respectively 0.72 ± 0.13cm and 0.66 ± 0.1cm, P<0.001 before and after the Dsv treatment.
2.3 liver makes hepatic tissue puncture pathologic finding to 15 gently routine~moderate chronic hepatitis patients during wearing treatment.4 examples after 6 months for the second time liver wear, as a result 3 routine hepatic tissues all have in various degree improve, show as inflammation in the hepatic tissue, necrosis alleviates, outgrowth fibrosis disappears, effective percentage is 75% (3/4), wherein 2 example check heptic fibrosis are 0 grade, effective percentage 50% (2/4).
3 discuss
Hepatitis B is the commonly encountered diseases frequently-occurring disease in China, wherein 1/3 can develop into chronic hepatopathy.The hepatic fibrosis incidence rate of chronic hepatitis can reach 85.15%.For this reason, slowly, the generation of blocking-up or reverse hepatic fibrosis team's minimizing liver cirrhosis or hepatocarcinoma is significant.The late world well-known scholar professor POPPer once pointed out emphatically: " who can stop or delay the generation of hepatic fibrosis, and who just will cure most of chronic hepatopathys.
The traditional Chinese medical science is thought the clinical syndrome complexity of chronic hepatitis, liver cirrhosis, but basic lesion mechanism is evil Sheng of just declining, and damp and hot blood stasis, stagnation of liver-QI spleen kidney qi blood deficiency, the stagnation of QI due to depression of the liver of holding concurrently to the greatest extent causes blood stasis.Meridian and vessels obstruction, not nourishing the liver of blood, crux are blood stasis.Blood stasis shows that the pathological change of chronic hepatitis, liver cirrhosis is the formation and the microcirculation disturbance of hepatic fibrosis.Recently research thinks that the Chinese medicine of hard masses softening and resolving, blood circulation promoting and blood stasis dispelling has the proliferation of fibrous tissue of inhibition liver, makes the fibrous tissue dissolving absorb, expand the liver vessel microcirculation improvement, helps the improvement and adjusting immunologic function of hepatocellular reparation and liver function.Drug therapy chronic hepatopathy 200 examples of the present invention.The result shows, clinical symptom remission, blood stasis doing well,improving after treating, and serum albumin increases, globulin descends, the spleen retraction of enlargement, and the every index of hepatic fibrosis all is significantly improved.Simultaneously B ultrasonic shows that inner diameter of portal vein, Dsv have and dwindles after treatment.Show that Drug therapy fibrosis in chronic liver disease patient of the present invention has good result at the aspects such as retraction of improving tcm symptom, hepatic tissue pathology change and serology hepatic fibrosis index, enlargement spleen.Except that individual patient has slight xerostomia and " hotness ", there are not other side reactions during the medication.Other relevant observations are still underway.
Three, pharmaceutical treatment chronic hepatitis fibrosis 200 routine results of the present invention report as follows.
1 clinical data
All cases are that be in hospital in the court or the chronic hepatitis patients with liver fibrosis of outpatient service.Be divided into treatment at random and organize 200 examples, male 170 examples, women 30 examples, 11~15 years old age.Matched group 100 examples, male 89 examples.Woman's 11 examples, 15~60 years old.Diagnosis meets the standard of nineteen ninety-five whole nation infectious disease parasitic disease academic conference revision.
2 Therapeutic Method
Treatment group medicine of the present invention under the identical condition of Primary Care, 3 times on the 1st, each 4,3 months is 1 course of treatment, takes 1~2 course of treatment.The matched group FUFANG DANSHEN PIAN, 3 times on the 1st, 1 time 4, oral, the course of treatment is the same.
Observe two groups of symptoms, sign before and after the treatment, serum wadding turbidity, albumin, globulin, 4 indexs of hepatic fibrosis [III] precollagen peptides (PIIIP), IV Collagen Type VI (IV-C) monoamine oxidase, MAO (MAO), hyaluronic acid (HA)], B ultrasonic looks into that hepatosplenomegaly is little, the splenic vein and inner diameter of portal vein etc.Full automatic biochemical apparatus and reagent that biochemistry detection is produced with U.S. Beckman company.The reagent that PIIIP produces with capital lion biological medicine company limited.The reagent that the reagent MAO that IV-C produces with the biological company limited of the gloomy hero in Shanghai produces with the biological company limited of Erie's health.The reagent that HA produces with Shanghai naval institute.Part hepatic tissue specimen percutaneous liver is worn acquisition.
3 therapeutic outcomes
3.1 after 1~2 course of treatment, clinical manifestation and lab testing result all have satisfied the improvement through Drug therapy of the present invention for symptom and lab index before and after two groups of treatments.The effective percentage of treatment group and matched group symptom, weakly be respectively 92.75%, 93.78%; Hepatalgia or discomfort are respectively 85.83%, 84.60%; Dim complexion is respectively 83.46%, 80.38%; The tongue ecchymosis is respectively 89.62%, 87.20%.
3.2 the splenic vein, inner diameter of portal vein change the preceding portal vein of treatment of control group, Dsv is respectively (1.223 ± 0.111) cm, (0.73 ± 0.143) cm; Be respectively (1.224 ± 0.102) cm, (0.170 ± 0.138) cm after the treatment, both compare P<0.01.Portal vein, Dsv are respectively (1.232 ± 0.118) cm, (0.723 ± 0.125) cm before the treatment of treatment group, are respectively (1.18 ± 0.09) cm, (0.665 ± 0.101) cm after the treatment, and both compare P<0.01.Compare for two groups the treatment back, is respectively P<0.01, P<0.05.
The effective percentage of treatment group and matched group biochemical analysis and ultrasound diagnosis, the wadding turbidity is respectively 83.80%, 82.30%; Albumin (<35g/L) be respectively 75.34%, 78.30%; Globulin (>35g/L) being respectively 84.26%, 90.97%, splenomegaly is respectively 86.96%, 31.50%.Wherein two groups of effective percentage of splenomegaly compare, and difference has highly significant, P<0.01.Index determinings such as hepatic fibrosis see Table 1.
3.3 that liver is worn is light to 15 examples during the treatment, the moderate chronic hepatitis is carried out liver puncture and done the pathology inspection.Drug induced hepatitis 1 example wherein, chronic hepatitis B 14 examples.4 customary the 2nd livers are worn after 6 months, and 3 routine hepatic tissues all have improvement in various degree as a result, see that inflammation, necrosis alleviate in the hepatic tissue, and outgrowth fiber disappears, and wherein 2 routine hepatic fibrosis are 0 grade.
After individual patient is taken medicine, feel slight xerostomia and the hotness in the course of treatment, do not find other side effect.
3 discuss
Hepatic fibrosis be chronic hepatitis progress for liver cirrhosis must be through approach, and primary hepatocarcinoma has substantial connection with liver cirrhosis.According to my institute's statistics, local 265 routine primary hepatocarcinoma confirm to merge the liver cirrhosis person through B ultrasonic and account for 76.19%.Show that blocking-up or reverse hepatic fibrosis are significant to the generation that reduces liver cirrhosis or primary hepatocarcinoma.Medicine of the present invention have invigorate blood circulation, thereby circulation of qi promoting, promotion hepatocyte restitution make clinical symptom remission, the blood stasis doing well,improving, serum albumin increases, globulin descends, enlargement spleen retraction, the every index of hepatic fibrosis is improved, and reaches desirable therapeutic.Data shows, Drug therapy chronic hepatopathy of the present invention all has effect preferably at the aspects such as spleen of improving patient's clinical symptoms, hepatic tissue pathology variation, serology liver fiber index and retraction enlargement, compare with the square medicine that with the blood circulation promoting and blood stasis dispelling is purpose merely, its mechanism of action and approach may show on the pharmacological characteristic of polytropism, stage construction, many target spots.
Hepatic fibrosis index before and after the table 1 liang group treatment (x ± s)
Group | The n/ example | HA/(ng/ml) | PIIIP/(μg/L) | IV-/(μg/L) | MAO/(U/L) |
The treatment of control group group | After treating before the preceding treatment of 100 treatments back 200 treatments | 396.16±306.75* 296.09±279.49** 366.0±277.41 144.0±138.2**ΔΔ | 1.394±0.212* 1.429±0.249 1.297±1.039 0.972±1.534* | 227.78±19.91 169.87±15.28** 204.82±186.4 95.67±52.36**ΔΔ | 47.25±1.29 47.83±1.71** 44.15±12.37 40.39±2.41**ΔΔ |
Relatively preceding with treatment, * P<0.05, * * P<0.01; Compare Δ Δ P<0.01 with matched group
Claims (8)
1, a kind of preparation for the treatment of hepatic fibrosis, it is characterized in that: make the raw materials of effective components medicine and consist of by weight, Radix Astragali 15-150 part, Radix Glehniae 15-150 part, Radix Rehmanniae 15-150 part, Radix Notoginseng 3-30 part, Fructus Crataegi 15-150 part, Semen Persicae 10-100 part, Rhizoma Chuanxiong 9-90 part, Poria 10-100 part, Radix Angelicae Sinensis 9-90 part, Radix Salviae Miltiorrhizae 15-150 part, Radix Paeoniae Rubra 15-150 part.
2, the preparation of treatment hepatic fibrosis according to claim 1 is characterized in that: described preparation is a said peroral dosage form on the pharmaceutics.
3. the preparation of treatment hepatic fibrosis according to claim 2 is characterized in that: described preparation is tablet or capsule.
4, according to the preparation method of claim 1 or 2 or 3 described treatment hepatic fibrosis preparations: it is characterized in that: its processing step is as follows:
(1) Radix Salviae Miltiorrhizae, Radix Notoginseng, the Radix Astragali three flavor Chinese medicines are directly pulverized, it is standby to get fine powder;
(2) with the remaining coarse powder of step (1) with other crude drug, adopt that the preparation method of existing Chinese patent medicine is carried out infusion, filtration, concentrated, ethanol precipitation, filtration, recovery ethanol, concentrate and put cold;
(3) with the fine powder of step (1) and step (2) to concentrate and put cold mixing of materials even, make medicament.
7, the preparation method of treatment hepatic fibrosis preparation according to claim 6: it is characterized in that: the fine powder described in the step (1) was that 80 mesh sieves or 80 orders are with top sieve.
8, the preparation method of treatment hepatic fibrosis preparation according to claim 6: it is characterized in that: the infusion technology described in the step (2) is, adds the water infusion 2 times, each infusion 1 hour, and merge and endure liquid.
9, the preparation method of treatment hepatic fibrosis preparation according to claim 6: it is characterized in that: the ethanol extraction technology described in the step (2) is, adds 95% ethanol and reaches 70% to containing the alcohol amount, leaves standstill 24 hours.
10, the preparation method of treatment hepatic fibrosis preparation according to claim 6: it is characterized in that: the filtrate behind the recovery ethanol described in the step (2) is concentrated into the thick paste shape.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100186641A CN100342879C (en) | 2005-05-03 | 2005-05-03 | Liver fibrosis treating prepn and its process |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100186641A CN100342879C (en) | 2005-05-03 | 2005-05-03 | Liver fibrosis treating prepn and its process |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1706443A CN1706443A (en) | 2005-12-14 |
CN100342879C true CN100342879C (en) | 2007-10-17 |
Family
ID=35580675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100186641A Expired - Fee Related CN100342879C (en) | 2005-05-03 | 2005-05-03 | Liver fibrosis treating prepn and its process |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100342879C (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103933430B (en) * | 2014-03-18 | 2016-11-23 | 吴侠 | Chronic hepatitis B medicine and preparation method thereof |
-
2005
- 2005-05-03 CN CNB2005100186641A patent/CN100342879C/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
抗纤I号胶囊抗肝纤维化的血清学和形态学实验研究 张月英 陈扬荣 王玉海 潘晨,山东中医药大学学报,第26卷第3期 2002 * |
Also Published As
Publication number | Publication date |
---|---|
CN1706443A (en) | 2005-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100342889C (en) | Chinese medicine for treating gout | |
CN1051237C (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
CN102462834A (en) | Medicinal composition for controlling blood sugar of diabetic | |
CN1541676A (en) | Health care medicine for enriching blood in puerperium and its preparation and uses | |
CN1840160A (en) | Powder for resisting hyperosteogeny | |
CN100342879C (en) | Liver fibrosis treating prepn and its process | |
CN1134298A (en) | "Dianxianningxiwan" pills-Chinese patent medicine for epilepsy | |
CN1857605A (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
CN1186067C (en) | Medicine for curing acute injury of muscle and tendon and its preparation method | |
CN1242767C (en) | Chinese medicinal compound preparation for treating liver fibrillation disease and its preparation method | |
CN1272054C (en) | Medicine for treating diabetes and its preparing process | |
CN101028349A (en) | Externally-applied medicine for treating prostatitis and prostatic accrementition | |
CN1326555C (en) | Chinese medicinal powder preparation for treating hepatic ascites | |
CN103417763B (en) | One treats osteoporotic pharmaceutical composition and its production and use | |
CN1657082A (en) | Oral Chinese medicinal composition for treating virus myocarditis | |
CN102512562B (en) | Pharmaceutical composition for treating ischemic cerebrovascular diseases and preparation method and applications thereof | |
CN1899528B (en) | Chinese patented medicine for treating psoriasis | |
CN101757369A (en) | Medicine composition for treating acute goutry arthritis and preparation process thereof | |
CN1189207C (en) | Chinese medicinal composition for improving human immunity and its preparation method | |
CN1943677A (en) | A Chinese traditional medicinal composition and its preparation method | |
CN1204916C (en) | Medicine for treating depression and its preparation method | |
CN1063074C (en) | Chinese herbs injection for treating oncoma (cancer) and preparation method | |
CN1256083C (en) | Medicine for boosting qi and nourishing blood and its prepatation method | |
CN1301733C (en) | Compound medicine for treating diabetes and its preparation process | |
CN107519237A (en) | A kind of pharmaceutical composition for preventing and treating rheumatoid arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071017 |